DE602007011043D1 - Tropan-prodrugs mit aktivität auf dem zns - Google Patents

Tropan-prodrugs mit aktivität auf dem zns

Info

Publication number
DE602007011043D1
DE602007011043D1 DE602007011043T DE602007011043T DE602007011043D1 DE 602007011043 D1 DE602007011043 D1 DE 602007011043D1 DE 602007011043 T DE602007011043 T DE 602007011043T DE 602007011043 T DE602007011043 T DE 602007011043T DE 602007011043 D1 DE602007011043 D1 DE 602007011043D1
Authority
DE
Germany
Prior art keywords
tropan
prodrugs
cns
activity
aromatic substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011043T
Other languages
English (en)
Inventor
Huw M Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Publication of DE602007011043D1 publication Critical patent/DE602007011043D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE602007011043T 2006-03-10 2007-03-12 Tropan-prodrugs mit aktivität auf dem zns Active DE602007011043D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78124506P 2006-03-10 2006-03-10
PCT/US2007/006169 WO2007106423A2 (en) 2006-03-10 2007-03-12 Tropane prodrugs with central nervous system activity

Publications (1)

Publication Number Publication Date
DE602007011043D1 true DE602007011043D1 (de) 2011-01-20

Family

ID=38510017

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602007013012T Active DE602007013012D1 (de) 2006-03-10 2007-03-12 Homotropane mit zns-aktivität
DE602007011043T Active DE602007011043D1 (de) 2006-03-10 2007-03-12 Tropan-prodrugs mit aktivität auf dem zns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602007013012T Active DE602007013012D1 (de) 2006-03-10 2007-03-12 Homotropane mit zns-aktivität

Country Status (8)

Country Link
US (3) US7432376B2 (de)
EP (4) EP1996584B1 (de)
JP (4) JP2009529532A (de)
CN (4) CN101400676A (de)
AT (3) ATE501143T1 (de)
BR (3) BRPI0707093A2 (de)
DE (2) DE602007013012D1 (de)
WO (4) WO2007106439A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201408115SA (en) * 2014-12-05 2016-07-28 Chakra Biotech Pte Ltd Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262428A (en) 1992-03-13 1993-11-16 Wake Forest University Biologically active tropane derivatives
US5760055A (en) 1992-03-13 1998-06-02 Wake Forest University Biologically active tropane derivatives
US5288872A (en) 1992-03-13 1994-02-22 Wake Forest University Compounds for treatment of neurodegenerative diseases
US5227385A (en) 1992-03-13 1993-07-13 Wake Forest University Method for treatment of neurodegenerative diseases
US5591854A (en) 1994-10-14 1997-01-07 Wake Forest University Enantioselective synthesis of seven-membered carbocycles and tropanes
GB9605065D0 (en) 1996-03-11 1996-05-08 Merck Sharp & Dohme Therapeutic agents
US6013242A (en) 1998-01-13 2000-01-11 Wake Forest University Tropane derivatives with selective binding to the serotonin reuptake transporters for treatment of mental illness and as intermediates in the formation of imaging diagnostic agents for depression
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2005037810A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de cyclopropylmethanones, leur preparation et leur utilisation en therapeutique
US20090203750A1 (en) * 2005-08-24 2009-08-13 Alan Kozikowski 5-HT2C Receptor Agonists as Anorectic Agents

Also Published As

Publication number Publication date
WO2007106439A2 (en) 2007-09-20
CN101400407A (zh) 2009-04-01
EP2004591A4 (de) 2009-11-11
US20070249646A1 (en) 2007-10-25
EP1996194B1 (de) 2011-03-09
CN101400652A (zh) 2009-04-01
EP1998771B1 (de) 2012-04-18
EP1998771A2 (de) 2008-12-10
EP2004591A1 (de) 2008-12-24
EP1996194A4 (de) 2009-11-11
WO2008127223A1 (en) 2008-10-23
EP1998771A4 (de) 2009-11-11
CN101400642A (zh) 2009-04-01
JP2009536644A (ja) 2009-10-15
BRPI0707096A2 (pt) 2011-04-19
EP1996194A2 (de) 2008-12-03
WO2007106423A3 (en) 2008-07-24
WO2007106439A3 (en) 2008-10-30
US7501453B2 (en) 2009-03-10
US20070232646A1 (en) 2007-10-04
BRPI0707097A2 (pt) 2011-04-19
CN101400676A (zh) 2009-04-01
ATE501143T1 (de) 2011-03-15
JP2009529535A (ja) 2009-08-20
US7432376B2 (en) 2008-10-07
US7851487B2 (en) 2010-12-14
EP1996584A4 (de) 2009-09-01
WO2007106423A2 (en) 2007-09-20
BRPI0707093A2 (pt) 2011-04-19
EP1996584A2 (de) 2008-12-03
ATE554069T1 (de) 2012-05-15
DE602007013012D1 (de) 2011-04-21
US20070244201A1 (en) 2007-10-18
EP1996584B1 (de) 2010-12-08
JP2009529532A (ja) 2009-08-20
ATE490963T1 (de) 2010-12-15
JP2009529534A (ja) 2009-08-20
WO2007106508A2 (en) 2007-09-20
WO2007106508A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
MX2020002184A (es) Composiciones y metodos para modular la expresion de la apolipoproteina (a).
EP3825403A3 (de) Verfahren und zusammensetzungen zur modulation der apolipoprotein(a)-expression
CL2009000782A1 (es) Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
MX2013011774A (es) Derivados de acido 3-fenilpropionico ramificados y su uso.
CY1118099T1 (el) Δισκια οξεικης ουλιπρισταλης
CL2014001212A1 (es) Compuestos heterobiciclicos condensados, inhibidores de fosfodiesterasa tipo 10a; composicion farmaceutica que los comprende; y metodo para tratar un trastorno seleccionado entre trastornos neurologicos y trastornos psiquiatricos.
MX2010001242A (es) Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
BRPI0707684A8 (pt) tratamento da esclerose tuberosa
PA8836101A1 (es) Inhibidores alfa7 nicotínicos del receptor de acetilcolina
AU2007257423A8 (en) Purine analogs
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
PH12013501321A1 (en) Phenoxymethyl heterocyclic compounds
MX2018005277A (es) Modular la expresion de apolipoproteina (a).
ATE490963T1 (de) Tropan-prodrugs mit aktivität auf dem zns
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
UY31335A1 (es) Tratamiento de sintomas vasomotores
WO2008097536A3 (en) Compositions and methods for treating psychiatric diseases and disorders
WO2009114088A3 (en) Fullerene therapies for inflammation
UA80189U (ru) Способ лечения генерализованного пародонтита i-ii степени хронического течения
UA87119U (uk) Спосіб моделювання бактеріального кератиту середнього ступеня тяжкості
MX355103B (es) Composicion para el tratamiento de desordenes inflamatorios e inmunes.
UA114409C2 (uk) Спосіб захисту корисних рослин або рослинного матеріалу для розмноження
UA69380U (ru) Способ профилактики кариеса зубов
RU2007148761A (ru) Способ снижения патологического влечения к этанолу в постабстинентный период